Dihydroergotamine mesylate injections are approved for the acute treatment of migraine with or without aura, and for the acute treatment of cluster headaches.
Dihydroergotamine mesylate injections are approved for the acute treatment of migraine with or without aura, and for the acute treatment of cluster headaches.
Migraine drugs make up a growing portion of pharmacy spend, driven by newer CGRP antagonists.
The study compares prices for medical services across 36 states from 2008 to 2024, representing 88% of workers’ comp benefits in the U.S.
In-depth reports cover topics ranging from an overview of the workers’ comp system to opioids, industry-specific trends, and more.
If passed, the bill would prevent the enforcement of laws on AI models and automated decision systems.
Healthe’s Kristine Kennedy speaks with Risk and Insurance magazine about how digital communication tools and emerging technologies are changing the landscape of workers’ comp.
Atzumi™ (dihydroergotamine (DHE)) nasal powder was approved for the treatment of acute migraine.
In celebration of the 15 year anniversary of RxInformer, the editorial staff looked back at past issues to understand what has changed – and what hasn’t.
While recreational marijuana laws may be tied to increases in claim frequency, medical payments and prescriptions decreased, including those for opioids.
Healthesystems VP of State & Industry Affairs comments on recent federal activity that creates potential impacts for workers’ comp.
A total of 14 reports capture workers’ comp data from 2018-2023 for 18 states, with information on medical payments and other metrics.
Healthe’s VP of Clinical Services, Silvia Sacalis, BS, PharmD, shares her thoughts with Business Insurance in this recent article.
A systematic review of 376 studies comprising almost 350,000 people with chronic pain saw 40% prevalence rates for depression and anxiety.
What they are, the benefits, how they’re currently covered by insurers, and future outlooks.
A bill in Massachusetts could require insurers to pay for marijuana, while ACOEM recommends against marijuana for chronic pain guidelines.
Approximately 38.8% of claims had one or more comorbidities, based on an analysis of 930,000 claims with at least 7 days lost time across 32 states.
Silvia Sacalis, VP of Clinical Services, chats with Business Insurance.
Drop by Booth #824 for a copy of the 15th Anniversary edition of RxInformer magazine, and to learn how we’re transforming healthcare.
The GLP-1 receptor agonist has been considered in shortage since 2022, but the FDA confirmed with manufacturers that presented and projected demand can now be met.
PBMs can reduce burden for payers, provide intuitive claims tools, provide effective customer support, and engage injured workers.
New York backpedaled on a PTSD presumption for all workers, while California considers a PTSD presumption for healthcare workers.
Despite decreases in injury frequency across all groups, younger workers still saw higher use of emergency departments.
So far, seven psilocybin therapy bills have been introduced in 2025, with three ketamine therapy bills.
Mike Theis has been promoted to AVP, Product Analytics and Business Strategy
A first-in-class medication, Journavx targets pain-signaling pathways involving sodium channels.
The seventh annual survey report highlights the top challenges and priorities for 515 industry stakeholders.
Various states are proposing modifications to existing presumptions to expand coverage for first responders.
A compound opioid/NOP receptor agonist demonstrated pain relief with a safety profile comparable to placebo.
Pandemic driven increases to provider vacancies have increased reliance on nurse practitioners and physician assistants.
Recent data insights, state proposals, and updates on federal rulemaking procedures.
Victoza® (liraglutide) injections are a GLP-1 receptor agonist, a drug class experiencing shortages due to their high demand.
Health trends to consider in this growing portion of the workforce.
The guidelines provide recommendations on using AI to demonstrate drug safety and effectiveness, and recommendations for AI-enabled medical devices.
Among many changes, the state is replacing AWP with a new pricing model.
Medical use would be legalized, with legal protections for patients and physicians.
How a good customer service center can create an exceptionally positive experience for customers, claims teams, and injured workers.
These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
Sleep deprivation and fatigue have far-reaching consequences in the workplace, from poor productivity to injury or death.
All workers will now have the right to file a claim for mental injuries, based upon extraordinary work-related stress incurred on the job.
A proposed bill would apply to male and female reproductive systems for firefighters and EMTs.
Private industry employers reported 2.6 million nonfatal workplace injuries and illnesses in 2023, down 8.4% from 2022.
We checked the stats and reviewed our readers’ favorite articles from RxInformer magazine to bring you a list of our most engaging content from 2024.
This drug has been approved for the treatment of multiple chronic inflammatory disorders.
128 million adults in the U.S. are affected by hypertension and cardiovascular diseases.
Recent data from CWCI and WCRI, plus clinical concerns.
As part of a legislative-mandated study on work-related PTSD, the survey could influence regulator objectives for 2025.
A recent study involving the compound DOI showed promising results in mice.
A new NCCI report found that hotter and colder temperatures were associated with higher claims frequency, as much as 10% higher in some cases.
Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.
Healthes’ AVP of Information Security, Tony Brown, discusses how cyber threats affect workers’ comp organizations.
NCCI hosted a recent webinar on opioid utilization, while Fair Health published a new Opioid Tracker tool to monitor state opioid data.
WCRI reports for Delaware and Philadelphia reported increases, matching patterns seen previously in other states.
These assistants must be under the supervision of a board-authorized provider.
A new issue of RxInformer magazine, plus Leaders Speak posts in WorkCompWire, featuring Sandy Shtab and Silvia Sacalis.
The benefits of different screening strategies and therapeutic interventions.
The push comes after a letter carrier died after working without air conditioning in 95° weather.
The FDA requested additional trial data, with researchers eager to continue psychedelic trials.
High-cost claims are defined as the top 5% of medical payments within 36 months of injury.
Stop by our educational session or visit our booth for the latest issue of RxInformer magazine.
